In-licencing

When appropriate, Advicenne in-licenses selected products to strengthen our product portfolio and/or to address Key Opinion Leaders (KOLs) demand on specific medical needs.

Out-licencing

In 2016, Advicenne sold ADV6209, an oral pediatric anesthetic for moderate sedation, to Primex Pharmaceuticals, a Swiss-based company.
Press Release

Academic and Scientific

Given Advicenne’s desire to improve the treatment of orphan or neglected diseases and to meet the high expectations of patients, we are always open to academic and scientific collaborations to allow us to access new perspectives and to share our knowledge.

European Projects

KIEKIDS is a European project financed by the European Commission (EU) to develop a new anti-epileptic for the treatment of black-out in children.